STAT+: Early data are promising for autoimmune disease drug from Roivant Sciences’ Immunovant
Results from an early study of an autoimmune disease drug from Roivant Sciences’ Immunovant showed the treatment could reduce a key immune marker in the blood, a promising signal.
Results released Tuesday from an early study of an autoimmune disease drug from Roivant Sciences’ Immunovant showed the treatment could reduce the levels of a key immune marker in the blood, a promising signal.
The results are only from a Phase 1 trial, but were anticipated because they were the first-in-human outcomes being reported for the antibody drug, IMVT-1402. The drug is in development for a number of autoimmune diseases and is part of a burgeoning class of treatments that block a receptor known as FcRn that, when activated, can trigger such conditions. Other companies working on FcRn inhibitors include Johnson & Johnson and Argenx.
Immunovant shares saw a big jump in pre-market trading.
What's Your Reaction?
